WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
PRNewsWire
·
2026-07-09
·
via The Tech Buzz - Press Releases
SHIJIAZHUANG, China, July 9, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。